Vivus, Inc.: VVUS (NASDAQ)
VIVUS Announces First Quarter 2002 Earnings Conference Call
MOUNTAIN VIEW, Calif.--April 16, 2002--VIVUS, Inc.
(Nasdaq NM:VVUS) today announced that the Company will hold a conference call to discuss first quarter 2002 results on Wednesday,April 17, 2002, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). The conference call can be heard live via audio webcast at the Company's website: www.vivus.com, and will be available for replay for 14 days.
VIVUS, Inc. is a pharmaceutical company engaged in the development of innovative therapies for the treatment of quality-of-life disorders in men and women, with a focus on sexual dysfunction. Current development programs target Female Sexual Dysfunction (FSD), Erectile Dysfunction (ED) and Premature Ejaculation (PE). The Company developed
and markets in the U.S. MUSE(R) (alprostadil) and ACTIS(R), two innovations in the treatment of erectile dysfunction, and has partnered with Abbott Laboratories (NYSE:ABT) for the internationalmarketing and distribution of its male transurethral ED products. In Canada, VIVUS has partnered exclusively with Paladin Labs (TSE:PLB) to market and distribute MUSE.
CONTACT: VIVUS, Inc.
Richard Walliser, 650/934-5200
ir@vivus.com
www.vivus.com
or
Lippert/Heilshorn & Associates, Inc.
Bruce Voss, 310/691-7100 (Investors)
bvoss@lhai.com
Jody Cain, 310/691-7100 (Investors)
jcain@lhai.com
Elissa Grabowski, 212/838-3777 (Media)
egrabowski@lhai.com
www.lhai.com |
